Treatment of Cancer Use Patent for EP4 antagonist Approved in Korea

On November 5, 2015 AskAt reported that it has received a notice of allowance dated November 5, 2015 from Korea Intellectual Property Rights Information Service (KIPRS) in connection with the Application No. 10-2011-7027678, a use patent of EP4 receptor antagonist for the treatment of Cancer (Press release, AskAt, NOV 5, 2015, View Source [SID1234535066]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!